A "Three-Plus-One" Evaluation Model for Clinical Research Management

Evaluation and the Health Professions

Volumn 36, Issue 4, 2013, Pages 464-477

  Dilts, David M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

CRM value; global evaluation; managerial evaluation; strategic evaluation

Indexed keywords

ARTICLE; CRM VALUE; GLOBAL EVALUATION; HUMAN; MANAGERIAL EVALUATION; MEDICAL RESEARCH; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PROGRAM EVALUATION; STRATEGIC EVALUATION; THEORETICAL MODEL;

CRM VALUE; GLOBAL EVALUATION; MANAGERIAL EVALUATION; STRATEGIC EVALUATION;

BIOMEDICAL RESEARCH; HUMANS; MODELS, THEORETICAL; PROGRAM EVALUATION;

EID: 84887430039     PISSN: 01632787     EISSN: 15523918     Source Type: Journal    
DOI: 10.1177/0163278713499019     Document Type: Article

References (38)

1. Benkler Y.The wealth of networks: How social production transforms markets and freedom. New Haven, CT: Yale University Press; 2006:.
2. Benkler Y.The Penguin and the Leviathan: The triumph of cooperation over self-interest. 2011). The Penguin and the Leviathan: The triumph of1st ed.). NewNew York, NY: Crown Business; 2011:.
3. Berwick D. M.A user's manual for the IOM's 'Quality chasm' report.Health Affairs. 2002;21:80-90.
4. Califf R. M.,Zarin D. A.,Kramer J. M.,Sherman R. E.,Aberle L. H.,Tasneem A.Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010.Journal of the American Medical Association. 2012;307:1838-1847.
5. Cheng S. K.,Dietrich M. S.,Dilts D. M.A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.Clinical Cancer Research. 2010;16:5557-5563.
6. Cheng S. K.,Hirsch B. R.,Califf R. M.,Tasneem A.,Schulman K. A.,Abernethy A. P.,Dilts D. M.Geographic and network analysis of oncology trials: Portfolio assessment of ClinicalTrials.gov.Journal of Clincal Oncology. 2012;30 (suppl):.
7. Conforti L. N.,Hess B. J.,Ross K. M.,Lynn L. A.,Holmboe E. S.Variability in obtaining institutional review board approval for quality improvement activities in residency programs.The Journal of Graduate Medical Education. 2012;4:106-108.
8. Clinical & Translational Science Awards. (2013a). CTSA: Clinical Research Management Key Function Committee. Retrieved fromhttp://www.ctsacentral.org/committee/clinical-research-management.
9. Clinical & Translational Science Awards. (2013b). Learn about CTSA. Retrieved fromhttps://http://www.ctsacentral.org/articles/learn.
10. Clinical & Translational Science Awards. (2013c). About the CTSA Consortium. Retireved fromhttps://http://www.ctsacentral.org/about-us/ctsa.
11. Dilts D. M.Early warning: An ailing canary in the mine.Journal of Clinical Oncology. 2010;28:3799-3800.
12. Dilts D. M. Paper presented at the CTSA Annual Evaluation Meeting; 2012Bethesda, MC; 2012.
13. Dilts D. M.,Cheng S. K.The importance of doing trials right while doing the right trials.Clinical Cancer Research. 2012;18:3-5.
14. Dilts D. M.,Cheng S. K.,Crites J. S.,Sandler A. B.,Doroshow J. H.Phase III clinical trial development: a process of chutes and ladders.Clinical Cancer Research. 2010;16:5381-5389.
15. Dilts D. M.,Peters C.,Cheng S. K.,Stadum S. Paper presented at the ASCO Quality Care Symposium; 2012; 2012.
16. Dilts D. M.,Rosenblum D.,Trochim W. M.A virtual national laboratory for reengineering clinical translational science.Science Translational Medicine. 2012;4:.
17. Dilts D. M.,Sandler A. B.Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.Journal of Clinical Oncology. 2006;24:4545-4552.
18. Dilts D. M.,Sandler A. B.,Baker M.,Cheng S. K.,George S. L.,Karas K. S.Processes to activate phase III clinical trials in a cooperative oncology group: The case of cancer and leukemia group B.Journal of Clinical Oncology. 2006;24:4553-4557.
19. Dilts D. M.,Sandler A. B.,Cheng S. K.,Crites J. S.,Ferranti L. B.,Wu A. Y.Abrams J.Steps and time to process clinical trials at the cancer therapy evaluation program.Journal of Clinical Oncology. 2009;27:1761-1766.
20. Dilts D. M.,Sandler A.,Cheng S.,Crites J.,Ferranti L.,Wu A.Comis R.Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group.Clinical Cancer Research. 2008;14:3427-3433.
21. George M. L.,Rowlands D.,Price M.,Maxey J.The Lean Six Sigma pocket toolbook: A quick reference guide to nearly 100 tools for improving process quality, speed, and complexity. New York, NY: McGraw-Hill; 2005:.
22. Greene S. M.,Geiger A. M.A review finds that multicenter studies face substantial challenges but strategies exist to achieve Institutional Review Board approval.Journal of Clinical Epidemiology. 2006;59:784-790.
23. Hirsch B. R.,Mitchell A.,Cheng S. K.,Tasneem A.,Schulman K. A.,Dilts D. M.,Abernethy A. P.Improving the impact of clinical research: A systematic analysis of kidney cancer trials.Journal of Clinical Oncology. 2012;30 (suppl):.
24. Johnson T.,Joyner M.,Depourcq F.,Drezner M.,Hutchinson R.,Newton K.Toussant K.Using research metrics to improve timelines: proceedings from the 2nd Annual CTSA clinical research management workshop.Clinical and Translational Science. 2010;3:305-308.
25. Kitterman D. R.,Cheng S. K.,Dilts D. M.,Orwoll E. S.The prevalence and economic impact of low-enrolling clinical studies at an academic medical center.Academic Medicine. 2011;86:1360-1366.
26. Massett H. A.,Parreco L. K.,Padberg R. M.,Richmond E. S.,Rienzo M. E.,Leonard C. E. R.Dilts D. M.AccrualNet: Addressing low accrual via a knowledge-based, community of practice platform.Journal of Oncology Practice. 2011;7:e32-e39.
27. McJoynt T. A.,Hirzallah M. A.,Satele D. V.,Pitzen J. H.,Alberts S. R.,Rajkumar S. V.Building a protocol expressway: The case of mayo clinic cancer center.Journal of Clinical Oncology. 2009;27:3855-3860.
28. McWilliams R.,Hoover-Fong J.,Hamosh A.,Beck S.,Beaty T.,Cutting G.Problematic variation in local institutional review of a multicenter genetic epidemiology study.Journal of the American Medical Association. 2003;290:360-366.
29. Metzger-Filho O.,de Azambuja E.,Bradbury I.,Saini K. S.,Bines J.,Simon S. D.Piccart-Gebhart M.Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: The adjuvant lapatinib and/or trastuzumab treatment optimization experience.Oncologist. 2013;18:134-140.
30. Miller T. J.,Sevastita V. S.,Chaitt D. G.,Tavel J. A.,Pierson J. F.Protocol development program: A novel approach to overcoming barriers to clinical research.Monitor (Assocication for Clinical Pharmacology). 2013;27:54-61.
31. Mintzberg H.Rise and fall of strategic planning. New York, NY: Free Press; 1994:.
32. Nass S. J.,Moses H. L.,Mendelsohn J.A national cancer clinical trials system for the 21st century: Reinvigorating the NCI Cooperative Group Program. New York, NY: National Academies Press; 2010:.
33. NIST. (2013). Baldrige performance excellence program. Retireved fromhttp://www.nist.gov/baldrige/.
34. Paller M. S.,Hostetler L.,Dykhuis D. A.Clinical trials at AHCs: The perspective of an academic clinical trials office.Academic Medicine. 2002;77:1201-1206.
35. Porter M. E.What is strategy? Published November. 1996;:.
36. Porter M. E.Competitive advantage: Creating and sustaining superior performance. New York, NY: Free Press; 2008:.
37. Prahalad C. K.,Hamel G.The core competence of the corporation.Harvard Business Review. 1990;68:79-93.
38. Supply chain operations reference Overview - Version 10.0. 2010).10.0 (10.0Cypress, TX: Author; 2010:.